Related references
Note: Only part of the references are listed.Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
Lina Han et al.
HAEMATOLOGICA (2020)
Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Felicetto Ferrara
BLOOD CANCER JOURNAL (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia
Jorge Antonio Elias Godoy Carlos et al.
CELLULAR ONCOLOGY (2020)
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia
Haijiao Zhang et al.
NATURE CANCER (2020)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
A critical regulator of Bcl2 revealed by systematic transcript discovery of lncRNAs associated with T-cell differentiation
Wiam Saadi et al.
SCIENTIFIC REPORTS (2019)
Statins enhance efficacy of venetoclax in blood cancers
J. Scott Lee et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
Haley E. Ramsey et al.
CANCER DISCOVERY (2018)
Pathways and mechanisms of venetoclax resistance
Prithviraj Bose et al.
LEUKEMIA & LYMPHOMA (2017)
Non-apoptotic functions of BCL-2 family proteins
Atan Gross et al.
CELL DEATH AND DIFFERENTIATION (2017)
A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3-or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia
Aaron D. Schimmer et al.
PLOS ONE (2014)
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Rongqing Pan et al.
CANCER DISCOVERY (2014)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)
Marina Konopleva et al.
CANCER RESEARCH (2008)
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death
R. Schickel et al.
ONCOGENE (2008)
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis
Mai Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Share Paper
